The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | The utility of ctDNA in colorectal cancer management
Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the uses of circulating tumor DNA (ctDNA) in colorectal cancer in clinical practice. Measuring ctDNA can enhance early detection and enable diagnosis of colorectal cancer, as well as determine the minimal residual disease (MRD) status in patients, as shown in the CIRCULATE-US (NCT04089631) study. Responses to chemotherapy and drug resistance can additionally be assessed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ
